MINERVA SURGICAL, IN

UTRS
Delayed Quote. Delayed  - 08/18 04:00:00 pm
1.99USD +1.53%
Valuation
Fiscal Period: December 2021 2022
Capitalization1 14857,4
Enterprise Value (EV)1 13969,5
P/E ratio -1,68x-1,75x
Yield --
Capitalization / Revenue 2,84x1,12x
EV / Revenue 2,68x1,36x
EV / EBITDA -4,79x-2,80x
Price to Book --
Nbr of stocks (in thousands) 28 81628 860
Reference price (USD) 5,141,99
Announcement Date 03/08/2022-
Previous period Next period
1 USD in Million
Estimates
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2021 2022
Net sales1 52,151,1
EBITDA1 -29,1-24,8
Operating profit (EBIT)1 -29,1-30,2
Operating Margin -55,9%-59,1%
Pre-Tax Profit (EBT)1 -21,5-32,6
Net income1 -21,5-32,6
Net margin -41,2%-63,9%
EPS2 -3,06-1,14
Dividend per Share --
Announcement Date 03/08/2022-
Previous period Next period
1 USD in Million
2 USD
Estimates
Finances - Leverage
Fiscal Period: December 2021 2022
Net Debt1 -12,1
Net Cash position1 8,62-
Leverage (Debt / EBITDA) 0,30x-0,49x
Free Cash Flow1 -23,02,00
ROE (Net Profit / Equities) --
Shareholders' equity1 --
ROA (Net Profit / Asset) -39,1%-30,9%
Assets1 54,9106
Book Value Per Share --
Cash Flow per Share --
Capex 0,58-
Capex / Sales 1,12%-
Announcement Date 03/08/2022-
Previous period Next period
1 USD in Million
Estimates
Financial Ratios
Size 2022e 2023e
Capitalization 57 M $ -
Enterprise Value (EV) 69,5 M $ 103 M $
Valuation 2022e 2023e
P/E ratio (Price / EPS) -1,75x -1,85x
Capitalization / Revenue 1,12x 1,01x
EV / Revenue 1,36x 1,22x
EV / EBITDA -2,80x -2,49x
Yield (DPS / Price) - -
Price to book (Price / BVPS) - -
Profitability 2022e 2023e
Operating Margin (EBIT / Sales) -59,1% -55,4%
Operating Leverage (Delta EBIT / Delta Sales) -1,87x -
Net Margin (Net Profit / Revenue) -63,9% -59,5%
ROA (Net Profit / Asset) -30,9% -40,8%
ROE (Net Profit / Equities) - -
Rate of Dividend - -
Balance Sheet Analysis 2022e 2023e
CAPEX / Sales   0 0
Cash Flow / CA - -
Capital Intensity (Assets / Revenue) 2,07x 1,46x
Financial Leverage (Net Debt / EBITDA) -0,49x -1,62x
EPS & Dividend